China Merchants Capital has co-led a series B round sized at almost $99.2m that also attracted existing shareholder Legend Capital.
Berry Oncology, a China-based developer of genetic testing technology for cancer, has received nearly $99.2m in a series B1 round backed by Legend Capital, the venture capital firm formed by conglomerate Legend Holdings, DealStreetAsia reported today.
China Merchants Capital, a joint venture of logistics services provider GLP and conglomerate China Merchants Group, led the round.
Qiming Venture Partners, Zhongjin Qichen Industry Equity Investment Fund, E Fund, Fujian Venture Investment Management, Xiamen C&D Emerging Industry Equity Investment and undisclosed investors also…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
